Pipeline

Optiscan has designed a platform technology which can improve patient and healthcare outcomes in many areas of clinical practice.

Our goal is to provide patients with certainty, transparency, and peace of mind. Our technology enables earlier detection and treatment of disease that ultimately leads to better outcomes.

For clinicians, our hand-held digital endomicroscopes can accelerate histopathological data acquisition, and help establish a new standard of care.

In life sciences, our technology offers researchers the opportunity to pursue their curiosity without compromise, and empowers them to enhance their research outcomes by generating high quality longitudinal study data.

Our probe form-factors can be designed to enable doctors to interrogate tissue through natural body orifices or surgical openings, and our development pipeline will target new clinical applications through in-house development and collaborations with established academic research institutions and companies alike.

Our technology enables real-time digital pathology. We are actively developing digital pathology platforms to enable real time collaboration between surgeons and pathologists. Instant assessment of images using Artificial Intelligence (AI) and Machine Learning (ML) is under development.

Optiscan is working on innovating and commercialising new technology solutions that enable informed decisions for healthcare globally and establish a new standard of care in digital pathology and precision image guided surgery.

Learn more about the potential of Optiscan technology within the operating theatre with Prof. Mark Preul (Director of Neurosurgery Research at the Barrow Neurological Institute, USA).

Optiscan is looking forward to innovating and commercialising new technology solutions that enable informed decisions for healthcare globally and establish a new standard of care in digital pathology and precision surgery.